 Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis Next steps include targeted approach to delivering Psychedelics including Psilocybin and Ketamine Englewood Cliffs NJ, July 09, 2021 GLOBE NEWSWIRE -- Silo Pharma, Inc. OTC QB: SILO, a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research Agreement with the University of Maryland, Baltimore. 